{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:50:27Z","timestamp":1790707827698,"version":"4.1.0"},"reference-count":49,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2015,7]]},"abstract":"<jats:p>\n                    Ceftolozane\/tazobactam is a novel antipseudomonal \u03b2\u2010lactam\/\u03b2\u2010lactamase inhibitor combination that is currently approved by the United States Food and Drug Administration for the treatment of complicated intraabdominal infections (\n                    <jats:styled-content style=\"fixed-case\">cIAI<\/jats:styled-content>\n                    ) and complicated urinary tract infections (\n                    <jats:styled-content style=\"fixed-case\">cUTI<\/jats:styled-content>\n                    ). It exhibits bactericidal properties through inhibition of bacterial cell wall biosynthesis, which is mediated through penicillin\u2010binding proteins (\n                    <jats:styled-content style=\"fixed-case\">PBP<\/jats:styled-content>\n                    s). Ceftolozane is a potent\n                    <jats:styled-content style=\"fixed-case\">PBP<\/jats:styled-content>\n                    3 inhibitor and has a higher affinity for\n                    <jats:styled-content style=\"fixed-case\">PBP<\/jats:styled-content>\n                    1b compared with other \u03b2\u2010lactam agents. Ceftolozane\/tazobactam differs from other cephalosporins due to its increased activity against some AmpC \u03b2\u2010lactamases and\n                    <jats:italic>Pseudomonas aeruginosa<\/jats:italic>\n                    . The addition of tazobactam provides enhanced activity against extended\u2010spectrum \u03b2\u2010lactamase (\n                    <jats:styled-content style=\"fixed-case\">ESBL<\/jats:styled-content>\n                    )\u2010producing Enterobacteriaceae and certain anaerobic organisms. Population pharmacokinetic studies for ceftolozane and ceftolozane\/tazobactam are best described by a two\u2010compartment model with zero\u2010order input and linear elimination. Similar to other cephalosporins, the best pharmacodynamic property to predict efficacy for ceftolozane\/tazobactam is a concentration that remains above the minimum inhibitory concentration (\n                    <jats:styled-content style=\"fixed-case\">MIC<\/jats:styled-content>\n                    ) for 40\u201350% of the dosing interval. For Enterobacteriaceae and\n                    <jats:italic>P.\u00a0aeruginosa<\/jats:italic>\n                    strains, the time above the\n                    <jats:styled-content style=\"fixed-case\">MIC<\/jats:styled-content>\n                    (T\u00a0&gt;\u00a0\n                    <jats:styled-content style=\"fixed-case\">MIC<\/jats:styled-content>\n                    ) needed to produce bactericidal activity was much less with ceftolozane than other cephalosporins, with T\u00a0&gt;\u00a0\n                    <jats:styled-content style=\"fixed-case\">MIC<\/jats:styled-content>\n                    requirements of approximately 30%. For currently approved indications, the dose of ceftolozane\/tazobactam is 1.5\u00a0g (ceftolozane 1\u00a0g\/tazobactam 0.5\u00a0g) intravenously every 8\u00a0hours given as a 1\u2010hour infusion. Ceftolozane has low plasma protein binding (20%) and is predominantly excreted unchanged in the urine (\u226592%). Dosage adjustments are required for moderate\u2010to\u2010severe renal impairment and in patients receiving hemodialysis. Based on data from clinical trials, adverse effects due to ceftolozane\/tazobactam do not differ considerably from other cephalosporins, with the most common being nausea, diarrhea, headache, and pyrexia. Ceftolozane\/tazobactam is a promising new agent for the treatment of\n                    <jats:styled-content style=\"fixed-case\">cIAI<\/jats:styled-content>\n                    and\n                    <jats:styled-content style=\"fixed-case\">cUTI<\/jats:styled-content>\n                    , including those caused by multidrug\u2010resistant gram\u2010negative organisms.\n                  <\/jats:p>","DOI":"10.1002\/phar.1609","type":"journal-article","created":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T06:45:45Z","timestamp":1435733145000},"page":"701-715","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":71,"title":["Ceftolozane\/Tazobactam: A Novel Cephalosporin\/\u03b2\u2010Lactamase Inhibitor Combination"],"prefix":"10.1002","volume":"35","author":[{"given":"Jonathan C.","family":"Cho","sequence":"first","affiliation":[{"name":"Department of Pharmacy Lee Memorial Health System Fort Myers Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mallory A.","family":"Fiorenza","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Lee Memorial Health System Fort Myers Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandy J.","family":"Estrada","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Lee Memorial Health System Fort Myers Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,7]]},"reference":[{"key":"e_1_2_15_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir153"},{"key":"e_1_2_15_3_1","doi-asserted-by":"publisher","DOI":"10.1086\/605630"},{"key":"e_1_2_15_4_1","doi-asserted-by":"publisher","DOI":"10.1086\/499819"},{"key":"e_1_2_15_5_1","doi-asserted-by":"publisher","DOI":"10.1086\/524891"},{"key":"e_1_2_15_6_1","unstructured":"Centers for Disease Control and Prevention.Antibiotic threats in the United States 2013. Available fromhttp:\/\/www.cdc.gov\/drugresistance\/threat-report-2013\/pdf\/ar-threats-2013-508.pdf. Accessed January 21 2015."},{"key":"e_1_2_15_7_1","doi-asserted-by":"publisher","DOI":"10.1086\/655995"},{"key":"e_1_2_15_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit152"},{"key":"e_1_2_15_9_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.2005.25.10part2.44S"},{"key":"e_1_2_15_10_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01041-09"},{"key":"e_1_2_15_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2007.01681.x"},{"key":"e_1_2_15_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-7125(05)70303-5"},{"key":"e_1_2_15_13_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02253-13"},{"key":"e_1_2_15_14_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01737-10"},{"key":"e_1_2_15_15_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01802-13"},{"key":"e_1_2_15_16_1","unstructured":"WagenlehnerF UmehO HuntingtonJ et\u00a0al.Efficacy and safety of ceftolozane\/tazobactam versus levofloxacin in the treatment of complicated urinary tract infections (cUTI)\/pyelonephritis in hospitalized adults: results from the phase 3 ASPECT cUTI trial [Poster eP449]. Presented at: European congress of clinical microbiology and infectious diseases (ECCMID). Barcelona Spain May 10\u201313 2014."},{"key":"e_1_2_15_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ097"},{"key":"e_1_2_15_18_1","unstructured":"U.S. National Institutes of Health.ClinicalTrials.gov. Available fromhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT02070757?term=ceftolozane%2Ftazobactam&rank=1. Accessed January 13 2015."},{"key":"e_1_2_15_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2008.07.085"},{"key":"e_1_2_15_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2007.11.074"},{"key":"e_1_2_15_21_1","unstructured":"Cubist Pharmaceuticals U.S.Zerbaxa (ceftolozane\/tazobactam) package insert.Lexington MA 2014."},{"key":"e_1_2_15_22_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01104-09"},{"key":"e_1_2_15_23_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00680-12"},{"key":"e_1_2_15_24_1","volume-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard \u2013 ninth edition","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2012"},{"key":"e_1_2_15_25_1","volume-title":"Performance standards for antimicrobial susceptibility testing; twenty\u2010fourth informational supplement","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2014"},{"key":"e_1_2_15_26_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00860-06"},{"key":"e_1_2_15_27_1","unstructured":"CabotG MuletX MoyaB et\u00a0al.Dynamics and mechanisms of resistance development to ceftazidime meropenem and ceftolozane\/tazobactam in wild\u2010type and mutator P.\u00a0aeruginosa strains. 52nd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2012). San Francisco CA September 9\u201312 2012. Poster C1\u20101970."},{"key":"e_1_2_15_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq248"},{"key":"e_1_2_15_29_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03681-14"},{"key":"e_1_2_15_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2010.03130.x"},{"key":"e_1_2_15_31_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01753-09"},{"key":"e_1_2_15_32_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.06349-11"},{"key":"e_1_2_15_33_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.35.6.1081"},{"key":"e_1_2_15_34_1","unstructured":"MillerB ChandorkarG UmehO et\u00a0al.Safety and pharmacokinetics (PK) of intravenous (IV) ceftolozane\/tazobactam (C\/T) 3\u00a0g every 8\u00a0hours (q8\u00a0h) and cumulative fraction of response (CFR) in plasma and epithelial lining fluid (ELF) in a simulated ventilator\u2010associated pneumonia (VAP) population [abstract no. A\u2010641 plus poster]. 52nd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco September 9\u201312 2012."},{"issue":"4","key":"e_1_2_15_35_1","first-page":"S433","article-title":"Pharmacokinetics of CXA\u2010101\/tazobactam in subjects with mild or moderate renal impairment","volume":"17","author":"Miller B","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"e_1_2_15_36_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02151-13"},{"key":"e_1_2_15_37_1","unstructured":"GeY LiaoS.CXA\u2010101 (CXA) population PK analysis and Monte Carlo (MC) Simulation for PK\/PD target attainment and dose regimen selection [abstract no. F1\u20102003 plus poster]. 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco September 12\u201315 2009."},{"key":"e_1_2_15_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.395"},{"key":"e_1_2_15_39_1","unstructured":"MarierJF TrinhM PhengLH et\u00a0al.Population PK analysis of intravenous CXA\u2010101 in subjects with complicated urinary tract infection including pyelonephritis [abstract no. PII\u201049 plus poster]. 112th annual meeting of the American Society for Clinical Pharmacology and Therapeutics. Dallas March 2\u20135 2011."},{"key":"e_1_2_15_40_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks246"},{"key":"e_1_2_15_41_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01752-10"},{"key":"e_1_2_15_42_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01590-12"},{"key":"e_1_2_15_43_1","unstructured":"HershbergerE MouksassiM SteenbergenJN et\u00a0al.CXA\u2010101\/tazobactam probability of target attainment using population pharmacokinetic analysis. Presented at 21st European Congress of Clinical Microbiology and Infectious Diseases and Twenty\u2010seventh International Congress of Chemotherapy. Milan Italy May 7\u201310 2011."},{"key":"e_1_2_15_44_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks343"},{"key":"e_1_2_15_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2014.04.017"},{"key":"e_1_2_15_46_1","unstructured":"JacquelineC DesessardC RoquillyA et\u00a0al.50% effective dose (ED50) determination of CXA\u2010101 (CXA) alone or in combination with tazobactam (TAZ) for treating experimental peritonitis in mice due to extended\u2010spectrum \u00df\u2010lactamase (ESBL)\u2010producing Escherichia coli (EC) strains: comparison with ceftazidime (CAZ) and piperacillin\/tazobactam (TZP) [abstract no. F1\u20102000 plus poster]. 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco September 12\u201315 2009."},{"key":"e_1_2_15_47_1","unstructured":"JacquelineC DesessardC BatardE et\u00a0al.ED50 determination of CXA\u2010101 (CXA) alone and in combination with tazobactam (TAZ) for treating experimental peritonitis in mice due to ESBL producing Klebsiella pneumoniae strains: comparison with ceftazidime (CAZ) and piperacillin\/tazobactam (TZP) [abstract no. B\u2010708 plus poster]. 50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Boston September 12\u201315 2010."},{"key":"e_1_2_15_48_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00049-14"},{"key":"e_1_2_15_49_1","unstructured":"U.S. National Institutes of Health.ClinicalTrials.gov. Available fromhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT02266706?term=ceftolozane%2Ftazobactam&rank=3. Accessed January 14 2015"},{"key":"e_1_2_15_50_1","unstructured":"UmehO CebrikD FriedlandI.A double\u2010blind randomized phase 2 study to compare the safety and efficacy of intravenous CXA\u2010101 (CXA) and intravenous ceftazidime (CTZ) in complicated urinary tract infection (cUTI) [abstract no. L1\u2010361A plus poster]. 50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Boston September 12\u201315 2010."}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fphar.1609","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fphar.1609","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.1609","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T17:32:44Z","timestamp":1761067964000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.1609"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":49,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["10.1002\/phar.1609"],"URL":"https:\/\/doi.org\/10.1002\/phar.1609","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7]]},"assertion":[{"value":"2015-07-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}